Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy

Phase 2

Completed

• Conditions: Peripheral Nervous System Diseases; Chemotherapy-Induced Peripheral Neuropathy

• Registration Number: NCT00041795
• Lead Sponsor: NeoTherapeutics

Brief Summary

This study will assess the safety and efficacy of Neotrofin in treating the peripheral neuropathy that results from chemotherapy for cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-01
• Status Verified: 2002-07
• Study First Submitted: 2002-07-16
• Study First Submitted QC: 2002-07-18
• Study First Posted: 2002-07-19
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (6)

Alta Bates Comprehensive Cancer Center; 🇺🇸 Berkeley, California, United States

NYU Medical Center; 🇺🇸 New York, New York, United States

Washington University School of Medicine; 🇺🇸 St. Louis, Missouri, United States

Providence Holy Cross Medical Center; 🇺🇸 Mission Hills, California, United States

Providence St. Joseph Medical Center; 🇺🇸 Burbank, California, United States

The Sarah Cannon Cancer Center; 🇺🇸 Nashville, Tennessee, United States